Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Target Lowered at Citizens Jmp

Rhythm Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Citizens JMP lowered its price target on Rhythm Pharmaceuticals from $166 to $160 but maintained a “market outperform” rating, implying about 40% upside from the prior close.
  • Analyst sentiment is broadly positive: 18 analysts rate the stock Buy, three Hold, and one Sell, for a consensus “Moderate Buy” and average target of $141.67.
  • Quarterly results beat expectations: Rhythm reported a loss of $0.61 per share versus an estimated $0.71 loss, while revenue of $92.13 million rose 79.6% year over year.
  • MarketBeat previews the top five stocks to own by December 1st.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) had its target price decreased by equities research analysts at Citizens Jmp from $166.00 to $160.00 in a research note issued on Friday, Benzinga reports. The firm presently has a "market outperform" rating on the stock. Citizens Jmp's price target indicates a potential upside of 40.05% from the company's previous close.

RYTM has been the subject of a number of other research reports. Canaccord Genuity Group set a $154.00 price target on shares of Rhythm Pharmaceuticals in a research report on Wednesday, August 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rhythm Pharmaceuticals in a report on Thursday, October 15th. Leerink Partners started coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, September 14th. They set an "outperform" rating and a $133.00 price objective on the stock. Citigroup reissued a "market outperform" rating on shares of Rhythm Pharmaceuticals in a report on Wednesday, August 5th. Finally, National Bank Financial set a $160.00 price objective on shares of Rhythm Pharmaceuticals in a report on Wednesday, August 5th. Eighteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $141.67.

Get Our Latest Stock Analysis on RYTM

Rhythm Pharmaceuticals Price Performance

RYTM traded down $2.55 on Friday, reaching $114.25. The company's stock had a trading volume of 283,859 shares, compared to its average volume of 865,437. Rhythm Pharmaceuticals has a 1 year low of $74.50 and a 1 year high of $122.20. The business's 50 day moving average is $97.93 and its 200 day moving average is $97.65. The stock has a market cap of $7.92 billion, a price-to-earnings ratio of -39.34 and a beta of 2.17.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.10. Rhythm Pharmaceuticals had a negative return on equity of 171.16% and a negative net margin of 69.03%. The company had revenue of $92.13 million for the quarter, compared to the consensus estimate of $85.56 million. During the same period in the previous year, the business earned ($0.82) EPS. Rhythm Pharmaceuticals's revenue for the quarter was up 79.6% compared to the same quarter last year. As a group, research analysts forecast that Rhythm Pharmaceuticals will post -4.90 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Rhythm Pharmaceuticals news, CFO Hunter C. Smith sold 62,774 shares of the business's stock in a transaction on Monday, August 31st. The shares were sold at an average price of $105.46, for a total transaction of $6,620,146.04. Following the completion of the sale, the chief financial officer owned 114,024 shares in the company, valued at $12,024,971.04. The trade was a 35.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christophe Jean sold 10,000 shares of the business's stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $109.66, for a total transaction of $1,096,600.00. Following the sale, the director owned 11,712 shares of the company's stock, valued at approximately $1,284,337.92. The trade was a 46.06% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 122,774 shares of company stock worth $12,850,246 over the last ninety days. 5.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC grew its position in shares of Rhythm Pharmaceuticals by 36.3% during the 2nd quarter. GAMMA Investing LLC now owns 364 shares of the company's stock valued at $40,000 after buying an additional 97 shares during the last quarter. Global Retirement Partners LLC bought a new position in Rhythm Pharmaceuticals in the second quarter worth about $51,000. EverSource Wealth Advisors LLC lifted its holdings in Rhythm Pharmaceuticals by 106.4% in the first quarter. EverSource Wealth Advisors LLC now owns 549 shares of the company's stock worth $48,000 after acquiring an additional 283 shares during the last quarter. Pinnacle Wealth Planning Services Inc. lifted its holdings in Rhythm Pharmaceuticals by 894.0% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 666 shares of the company's stock worth $63,000 after acquiring an additional 599 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in Rhythm Pharmaceuticals by 9.1% in the third quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the company's stock valued at $155,000 after acquiring an additional 136 shares during the period.

About Rhythm Pharmaceuticals

(Get Free Report)

Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts, and its work centers on the melanocortin-4 receptor pathway, which helps regulate hunger and energy balance. Its commercial product, IMCIVREE (setmelanotide), is approved in the United States and Europe for certain forms of genetically defined obesity, including obesity associated with Bardet-Biedl syndrome and specific gene deficiencies.

Further Reading

Analyst Recommendations for Rhythm Pharmaceuticals (NASDAQ:RYTM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Rhythm Pharmaceuticals Right Now?

Before you consider Rhythm Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.

While Rhythm Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines